William A Wood Jr, MD - Radiology in Newport News, VA

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

News Archive

Quality of health care improves in states where APRNs are fully independent

As America's population ages, life spans lengthen and more individuals enroll in insurance plans under the Affordable Care Act, the need for health care professionals will increase. The Association of American Medical Colleges estimates that the health care market will fall short of demand by 45,000 primary care physicians in 2020. Many states do not allow advanced practice registered nurses (APRNs) to perform primary care duties to their full potential; however, University of Missouri researchers say APRNs can help relieve the shortage of healthcare workers and expand access to care for underserved populations.

High quality diet during mid-to-late adulthood may prevent adverse metabolic consequences

A new study in Obesity investigated the impact of diet quality in mid-to-late-adulthood on visceral and liver fat not solely relying on Body Mass Index.

New trial aims to prolong remission for pediatric leukemia patients treated with T-cell immunotherapy

After phase 1 results of Seattle Children's Pediatric Leukemia Adoptive Therapy trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia into complete initial remission, researchers have now opened a first-in-human clinical trial aimed at reducing the rate of relapse after the therapy, which is about 50 percent.

Genervon completes GM604 Phase 2a clinical trial for amyotrophic lateral sclerosis

Genervon Biopharmaceuticals LLC today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification. A full analysis of the trial's results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon's novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.

Read more News

› Verified 5 days ago